Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Anticancer composition and use thereof

A technology of composition and use, applied in the field of preparing medicine for treating cancer

Active Publication Date: 2021-04-30
SHANDONG LANJIN PHARMA
View PDF4 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Crude collagenase also contains other hydrolytic enzymes, so it is prone to other unexpected side effects

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Anticancer composition and use thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0056] Example 1 Effects of Different Doses of Collagenase on the Growth of Rectal Tumors

[0057] Will 2x10 5A rectal cancer cell was subcutaneously injected into the quarter rib of the mice, and after 7 days of tumor growth, they were divided into the following 10 groups (6 rats in each group, see Table 1). Group 1 was the control group, groups 2-4 were collagenase Ⅱ treatment groups, groups 5-7 were collagenase Ⅳ treatment groups, and groups 8-10 were MMP-7 treatment groups. The drug was injected into the tumor, and the dose was calculated in kilograms of body weight (mg / kg) (see Table 1 for the specific dose), administered once a day for a total of 3 times. The tumor volume was measured on the 15th day after treatment, and the treatment effects of each group were compared (see Table 1). The activity of collagenase II used was 342 U / mg, the activity of collagenase IV was 180 U / mg, and the activity of MMP-7 was 186 U / mg. The activity of MMP-8 (collagenase II) in other exa...

Embodiment 2

[0063] Example 2 Comparison of Inhibitory Effects of Collagenase II on Thyroid Cancer When Administered Through Different Routes

[0064] Will 8x10 5 Thyroid carcinoma cells were subcutaneously injected into the quarter ribs of mice. After 7 days of tumor growth, they were divided into the following 10 groups (6 rats in each group, see Table 2), and collagenase II was injected through different routes. Drug doses are calculated in kilograms of body weight (mg / kg). The administration methods were tail vein injection (IV), intratumoral injection (IT) and intraperitoneal injection (IP). Administration once a day, a total of 3 times. The tumor volume was measured on the 15th day after treatment, and the treatment effects of each group were compared (see Table 2).

[0065] Table 2

[0066] Group (n=6) receive treatment Tumor volume (mm 3 )

[0067] As shown in the results in Table 2, different routes of administration of collagenase II have significant difference...

Embodiment 3

[0068] Example 3 Comparison of Inhibitory Effects of Collagenase II on Liver Cancer When Administered Through Different Routes

[0069] 5x105 liver cancer cells were subcutaneously injected into the quarter ribs of mice, and after 7 days of tumor growth, they were divided into the following 10 groups (6 rats in each group, see Table 3), and collagenase II was injected through different routes. Group 1 is the control group, groups 2-4 are collagenase II intratumoral injection (IT) group, groups 5-7 are collagenase II peritumoral injection (PT) group, and groups 8-10 are collagenase II subcutaneous injection group. Injection (SC, 1-2 cm from tumor margin) group. The dosage of the medicine is calculated according to kilogram body weight (U / kg), and each milliliter injection contains 1000U collagenase II. Administration once a day, a total of 3 times. The tumor volume was measured on the 15th day after treatment, and the treatment effects of each group were compared (see Table 3...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The present application provides an anticancer composition comprising an anticancer active ingredient and a pharmaceutically acceptable carrier, wherein the anticancer active ingredient comprises collagenase II, collagenase IV or a combination thereof, preferably collagenase II. The present application also provides the use of the anticancer composition in the preparation of a medicament for the treatment of cancer. The anticancer composition of the present invention is suitable for intratumoral injection or implantation, peritumoral injection or implantation, and intratumoral injection or implantation after cancer surgery. The anticancer composition can be made into various pharmaceutical dosage forms, preferably injection.

Description

technical field [0001] The present application relates to an anticancer composition and a method for treating cancer, in particular, to an anticancer composition containing collagenase and its use in the preparation of medicines for treating cancer. Background technique [0002] According to China News Weekly (April 07, 2013), one person is diagnosed with cancer every 6 minutes across the country, 8,550 people become cancer patients every day, and one person dies of cancer every seven to eight people. In the next 10 years, the incidence and mortality of cancer in China will continue to rise. [0003] Cancer metastasis is the main cause of treatment failure in cancer patients. The metastasis of cancer is a complex multifactorial process, in which matrix metalloproteinases (Matrix Metalloproteinases, MMPs) play an important role in this process (Kumar A, Collins HM, Scholefield JH, Watson SA: Increased type-IV collagenase (MMP -2 and MMP-9) activity following preoperative ra...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Patents(China)
IPC IPC(8): A61K38/48A61P35/00A61P35/04
Inventor 孔庆忠苏红清孙明明闫立
Owner SHANDONG LANJIN PHARMA
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com